Heated Intraperitoneal Chemotherapy and Gastrectomy for Gastric Cancer With Positive Peritoneal Cytology

National Cancer Institute (NCI)27 enrolled

Overview

Background: \- Gastric cancer is a common and serious cancer. Standard treatment is chemotherapy drugs. Researchers want to see if a new treatment helps. It is surgical removal of the cancer and heated chemotherapy delivered to the abdominal cavity called Hyperthermic intraperitoneal chemotherapy (HIPEC). Objective: \- To test if surgical removal of tumors plus heated intraperitoneal chemotherapy can improve survival in people with gastric cancers. Eligibility: \- People ages 18 and older with gastric cancer who can have most tumors surgically removed Design: * Participants will be screened with: * Medical history * Physical exam * Blood, urine, and heart tests * Scans * Tissue sample from previous surgery * Endoscopy with biopsy: A tube with a camera goes through the mouth and into the stomach. It and takes a sample of stomach tissue. Participants may get medicine to make them drowsy. * Laparoscopy: Small cuts are made in the abdomen. A thin tube with a light and camera is inserted into the abdomen. Participants sleep through the procedure. Participants will stay in the hospital. They will have: * Surgery to remove as many tumors as possible. * HIPEC for 60 minutes: Two thin tubes are put into the abdomen. Two chemotherapy drugs are given through one tube. They are drained out through another at a temperature a few degrees above normal body temperature. Another drug is given in a vein. * Recovery for 7-21 days: Participants will have tubes in their stomach and bladder and intravenous (IVs) for a few days. They will get pain medicine, IV fluids, antibiotics, and blood transfusions as needed. * Participants will have visits every few months for 3 years, then one a year. Visits include physical exam, blood tests, and scans. They also include dietary assessment and questions.

Background: * An estimated 24,590 cases of gastric adenocarcinoma are diagnosed annually in the United States (U.S.). * The peritoneal surface is a site of metastasis found often at time of diagnosis and is a common (40%) site of recurrence. * Laparoscopy with peritoneal lavage and cytopathologic analysis is a staging modality that can identify a subset of patients with microscopic peritoneal metastasis prior to consideration for definitive surgical therapy. * Intraperitoneal chemotherapy has been employed in advanced gastric cancers and as an adjuvant with an associated improvement in survival in systematic reviews. Objectives: \- Determine the overall survival in patients with cytology-positive gastric cancer treated with Hyperthermic intraperitoneal chemotherapy (HIPEC) and gastrectomy. Eligibility: * Histologically confirmed adenocarcinoma of the stomach. * Cytopathologic evidence of peritoneal carcinomatosis. * Medically fit for systemic chemotherapy, HIPEC and gastrectomy. Design: \- Single arm, Phase II study of HIPEC and gastrectomy.

Interventions

SurgeryPROCEDURE

Heated Intraperitoneal Chemotherapy (HIPEC) with gastrectomy using cisplatin, mitomycin C and sodium thiosulfate

CisplatinDRUG

Cisplatin (90 mg/m\^2) will be administered via circuit to the peritoneal cavity

Mitomycin CDRUG

Mitomycin C 10 mg/m\^2 will be administered via circuit to the peritoneal cavity

Sodium ThiosulfateDRUG

Sodium thiosulfate will be administered by continuous intravenous infusion starting immediately prior to the chemotherapy perfusion and continuing for a total of 12 hours.

Tumor BiopsyPROCEDURE

At screening, baseline (if not done at screening) and operation (as clinically indicated).

CT C/A/PDIAGNOSTIC_TEST

At screening, baseline (if not done at screening), post op care, post-discharge visits/follow-up, semi-annual follow-up and annual follow-up.

PET-CTDIAGNOSTIC_TEST

At screening, baseline (if not done at screening), post op care, post-discharge visits/follow-up, semi-annual follow-up and annual follow-up.

MRIDIAGNOSTIC_TEST

If computed tomography (CT) contraindicated.

EKGDIAGNOSTIC_TEST

At screening and baseline (if not done at screening).

Eligibility

Sex: ALLMin age: 18 Years

Medical Language ↔ Plain English

* INCLUSION CRITERIA: * Patients must have histologically or cytologically confirmed gastric adenocarcinoma or gastroesophageal junction (Siewert I-III) adenocarcinoma confirmed by the Laboratory of Pathology, national Cancer Institute (NCI). * Must have received systemic chemotherapy, minimum 3 months or maximum 6 months, prior to enrollment * Systemic therapy should consist of at least fluoropyrimidine-based and/or platinum-based chemotherapy * Trastuzumab may be added for human epidermal growth factor receptor 2 (HER2)-neu over-expressing cancers as clinically indicated * Last dose of chemotherapy within 8 weeks of enrollment with recovery to Grade 1 from chemotherapy-related toxicities * Documentation of chemotherapy administration must be obtained * Subradiographic and/or cytopathologic evidence of peritoneal carcinomatosis found at staging laparoscopy. * Documentation of cytopathologic diagnosis of malignant peritoneal cytology in the absence of disseminated peritoneal disease must be obtained. If cytologic analysis reveals atypical cells of undetermined significance, a repeat lavage with cytopathologic analysis will be performed and must demonstrate evidence of malignancy. * Limited peritoneal involvement found at staging laparoscopy or on final pathology that is deemed completely resectable is permitted * Age \>18 years. * Eastern Cooperative Oncology Group (ECOG) performance status \<2 * Patients must have normal organ and marrow function as defined below: * hemoglobin \> 8.0 g/dL * absolute neutrophil count greater than or equal to 1,000/mcL * platelets greater than or equal to100,000/mcL * total bilirubin within normal institutional limits * Aspartate aminotransferase (AST)Serum glutamic-oxaloacetic transaminase (SGOT)/Alanine aminotransferase (ALT)Serum glutamic-pyruvic transaminase (SGPT) less than or equal to 2.5 X institutional upper limit of normal * creatinine \< 1.5 mg/dl * estimated glomerular filtration rate (GFR) (creatinine clearance) greater than or equal to 60 mL/min/1.73 m\^2. * Physiologically able to undergo heated intraperitoneal chemotherapy (HIPEC) and gastrectomy * No history of malignancy within 2 years of enrollment except for basal cell carcinoma of the skin, squamous cell skin cancer or carcinoma in situ of the cervix. * Ability of subject to understand and the willingness to sign a written informed consent document * Previous exploratory laparotomy or laparoscopy with tissue biopsy or peritoneal lavage is permitted. * Women of child-bearing potential and men must agree to use adequate contraception (hormonal or barrier method of birth control; abstinence) prior to study entry and for the duration of study participation. Should a woman become pregnant or suspect she is pregnant while she or her partner is participating in this study, she should inform her treating physician immediately * Subjects must agree to co-enrollment on the tissue collection protocol 13C0176, Tumor, Normal Tissue and Specimens from Patients Undergoing Evaluation or Surgical Resection of Solid Tumors. EXCLUSION CRITERIA: * Patients who are receiving any investigational agents * Disseminated extra-peritoneal or solid organ metastases * Includes carcinomatosis associated with clinically or radiographically evident ascites (greater than 500cc) --Excludes greater omentum and ovarian metastases * Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements. * Pregnant women are excluded from this study because HIPEC and gastrectomy have not been studied in pregnant women and has the potential for teratogenic or abortifacient effects. Because there is an unknown but potential risk for adverse events in nursing infant's secondary to treatment of the mother with HIPEC and gastrectomy, breastfeeding should be discontinued if the mother is treated on this study. * Human immunodeficiency virus (HIV)-positive patients may be considered for this study only after consultation with a National Institute of Allergy and Infectious Diseases (NIAID) physician.

Outcomes

Primary Outcomes

Overall Survival (OS)

OS is defined as the median amount of time a participant survives after therapy.

Time frame: 53.7 months

Secondary Outcomes

Intraperitoneal Progression Free Survival (IPFS) at 6 Months, 12 Months and 18 Months

Intraperitoneal progression free survival is defined as the median amount of time a participant survives from date of operation (hyperthermic intraperitoneal chemotherapy (HIPEC) and gastrectomy) without intraperitoneal disease progression after treatment. Intraperitoneal progression is defined as new, large volume ascites with or without associated peritoneal nodularity or thickening determined by radiographic imaging, cytopathology or histopathology.

Time frame: 6 months, 12 months and 18 months

Extra-peritoneal Disease-free Survival

Extra-peritoneal disease-free survival is defined as the median amount of time a participant survives from date of surgery to the date of first observation of progressive disease at sites other than the peritoneal surface (e.g., liver, intra-abdominal lymph nodes, abdominal wall soft tissues, and any other solid organs) determined by radiographic imaging (i.e., computed tomography, magnetic resonance imaging, and/or positron emission tomography).

Time frame: 48.9 months

Number of Treatment Related Serious and/or Non-serious Adverse Events by Type

The number of treatment related serious and/or non-serious adverse events by type related to research treatments was assessed by the Common Terminology Criteria for Adverse Events (CTCAE v5.0). A non-serious adverse event is any untoward medical occurrence. A serious adverse event is an adverse event or suspected adverse reaction that results in death, a life-threatening adverse drug experience, hospitalization, disruption of the ability to conduct normal life functions, congenital anomaly/birth defect or important medical events that jeopardize the patient or subject and may require medical or surgical intervention to prevent one of the previous outcomes mentioned.

Time frame: Up to 1646 days